Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis

doi:10.1002/cam4.4350

	Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis
	Li, Zheng 1,2,3,4; Li, Qiang 1,2,3,5; Wang, Xiaohu 3,4; Chen, Weiqiang 1,2,3,5; Jin, Xiaodong 1,2,3,5; Liu, Xinguo 1,2,3,5; Ye, Fei 1,2,3,5; Dai, Zhongying 1,2,3,5; Zheng, Xiaogang 1,2,3,5; Li, Ping 1,2,3,5
刊名	CANCER MEDICINE
	2021-10-16
页码	19
关键词	COVID-19 hepatocellular carcinoma hyperthermia ablation meta-analysis SARS-CoV-2 transarterial chemoembolization
ISSN号	2045-7634
DOI	10.1002/cam4.4350
通讯作者	Li, Qiang(liqiang@impcas.ac.cn)
英文摘要	Background and aims The existing evidence has indicated that hyperthermia ablation (HA) and HA combined with transarterial chemoembolization (HATACE) are the optimal alternative to surgical resection for patients with hepatocellular carcinoma (HCC) in the COVID-19 crisis. However, the evidence for decision-making is lacking in terms of comparison between HA and HATACE. Herein, a comprehensive evaluation was performed to compare the efficacy and safety of HATACE with monotherapy. Materials and Methods Worldwide studies were collected to evaluate the HATACE regimen for HCC due to the practical need for global extrapolation of applicative population. Meta-analyses were performed using the RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). Results Thirty-six studies involving a large sample of 5036 patients were included finally. Compared with HA alone, HATACE produced the advantage of 5-year overall survival (OS) rate (OR:1.90; 95%CI:1.46,2.46; p < 0.05) without increasing toxicity (p >= 0.05). Compared with TACE alone, HATACE was associated with superior 5-year OS rate (OR:3.54; 95%CI:1.96,6.37; p < 0.05) and significantly reduced the incidences of severe liver damage (OR:0.32; 95%CI:0.11,0.96; p < 0.05) and ascites (OR:0.42, 95%CI:0.20,0.88; p < 0.05). Subgroup analysis results of small (<= 3 cm) HCC revealed that there were no significant differences between the HATACE group and HA monotherapy group in regard to the OS rates (p >= 0.05). Conclusions Compared with TACE alone, HATACE was more effective and safe for HCC. Compared with HA alone, HATACE was more effective for non-small-sized (>3 cm) HCC with comparable safety. However, the survival benefit of adjuvant TACE in HATACE regimen was not found for the patients with small (<= 3 cm) HCC.
资助项目	China Postdoctoral Science Foundation[2019M663860] ; National Key Research Program of China[2018YFC0115700] ; National Key Research Program of China[2018YFC0115702] ; National Natural Science Foundation of China[11875299] ; National Natural Science Foundation of China[U1532264] ; Key Deployment Project of Chinese Academy of Sciences[SW--222] ; West Light Foundation of Chinese Academy of Sciences[29Y86205]
WOS关键词	TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION ; RADIOFREQUENCY ABLATION ; MICROWAVE ABLATION ; COMBINED THERAPY ; COMBINATION THERAPY ; CLINICAL CHARACTERISTICS ; SURGICAL RESECTION ; THERMAL ABLATION ; CANCER-TREATMENT ; RISK-FACTORS
WOS研究方向	Oncology
语种	英语
出版者	WILEY
WOS记录号	WOS:000707557000001
资助机构	China Postdoctoral Science Foundation ; National Key Research Program of China ; National Natural Science Foundation of China ; Key Deployment Project of Chinese Academy of Sciences ; West Light Foundation of Chinese Academy of Sciences
内容类型	期刊论文
源URL	[http://119.78.100.186/handle/113462/136210]
专题	中国科学院近代物理研究所
通讯作者	Li, Qiang
作者单位	1.Gansu Prov Key Lab Basic Res Heavy Ion Radiat App, Lanzhou, Peoples R China 2.Chinese Acad Sci, Key Lab Heavy Ion Radiat Biol & Med, Lanzhou, Peoples R China 3.Chinese Acad Sci, Inst Modern Phys, 509 Nanchang Rd, Lanzhou 730000, Peoples R China 4.Lanzhou Heavy Ion Hosp, Lanzhou, Peoples R China 5.Univ Chinese Acad Sci, Beijing, Peoples R China
推荐引用方式 GB/T 7714	Li, Zheng,Li, Qiang,Wang, Xiaohu,et al. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis[J]. CANCER MEDICINE,2021:19.
APA	Li, Zheng.,Li, Qiang.,Wang, Xiaohu.,Chen, Weiqiang.,Jin, Xiaodong.,...&Liu, Ruifeng.(2021).Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis.CANCER MEDICINE,19.
MLA	Li, Zheng,et al."Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta-analysis".CANCER MEDICINE (2021):19.